posted
DNAPrint Genomics Launches Personal, Confidential DNA Storage Service New Offering Complements DNA Testing Products and Is Seen as Aiding Health Diagnostics and Investigations or as a Holiday Gift DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced the launch of its personal DNA Storage Service, designed to complement the Company's comprehensive line of genetic ancestry products and to ensure the confidentiality of personal DNA data for future testing or personal use.
"We offer this service because everyone should establish genetic profiles for themselves and their children," stated DNAPrint Genomics President and Chief Executive Officer Richard Gabriel. "The Company's line of DNA ancestry products, such as AncestryByDNA(TM) and EuroDNA(TM), can be used in this way and to explore family heritage at the same time. DNA testing may also be used to predict individual sensitivities or side effects to certain drugs. Moreover, with the current backlog of cases at various investigative agencies, we feel that establishing a sample file with DNAPrint could help speed up the process of finding anyone -- especially children -- who may go missing. For these reasons among many, we would certainly encourage individuals to have their DNA tested at the same time that it is stored."
The basic DNA storage plan is available at an initial cost of $39.00 and is renewed annually. The Company also offers fully paid storage at a discount for 5-year increments. An STRmap analysis service is also offered for those wanting their DNA to be typed at 16 genetic markers that may be used for human identity in addition to storage. The Company's AncestryByDNA(TM) and EuroDNA(TM) products are available separately and can be used to trace genetic heritage among the four anthropological groups: Native American; East Asian; Sub-Saharan African (areas south of the Sahara Desert); Indo-European (Europe, Middle East, North Africa, Western Asia).
"We also appreciate that this is the time of year when people are looking for unusual and unique gift ideas," Mr. Gabriel said. "This service, in conjunction with DNAPrint's complete line of genetic history products, would certainly qualify as a special gift, providing a great opportunity to share a new understanding of one's family tree and help strengthen the bonds between generations."
"DNA is very stable when stored under the proper conditions and DNAPrint is an expert in this area," said Anthony Frudakis, Ph.D., Chief Scientific Officer and founder of DNAPrint. "There have been many requests from the general public about storing DNA, so the Company has put together a retrieval and storage package that is painless and doesn't involve the use of blood. Storing DNA can be important to couples and families who may want to have their DNA evaluated and have the results reported back to them."
DNA is retrieved using the DNAPrint Genomics, Inc. non-invasive collection product, which in the past has been used to safely collect more than 26,000 samples. Samples are taken from cheek cells using a swab and instructions that come with each kit. The DNA is stored in a moisture-free environment with a quality assurance monitoring program. DNA storage under dry conditions is the key to long lasting DNA. Experts note that microbes, fungi and other organisms do not survive without moisture, so a dry, cool environment significantly lengthens the DNA storage life. Of course, the person submitting the sample retains ownership.
DNAPrint Genomics, Inc. is a premier testing laboratory offering the only autosomal test for Bio-Geographical Ancestry called AncestryByDNA(TM). The forensic version of this test, DNAWitness(TM) 2.5, has been used in over 150 cases to date. This experience in the forensic field, as well as work with ancient DNA samples, has developed a level of knowledge and skill that will benefit the DNA storage program. In addition to the AncestryByDNA(TM) and DNAWitness(TM) test, DNAPrint offers mitochondrial, Y-chromosome, and paternity testing. The DNA storage program and its upgrade will allow customers to take advantage of DNAPrint's present and future services and products as they become available. DNA storage assists families, couples and individuals in preserving their DNA as the age of DNA testing advances.
"DNA technology is advancing so rapidly that it's almost impossible to predict what the next ten to twenty years will hold," stated Mr. Gabriel. "Storing an individual's DNA may open up a world of options in specialized medicine for those that have preserved their DNA. When new tests come out, if the person is interested, we can screen their DNA rapidly and provide them with new information on their potential response to drugs or to the progression of disease. All of our services are compliant with HIPPA and we maintain the strictest confidentiality."
To order the new services, call customer service at 941-366-3400, extension 230.
About DNAPrint Genomics, Inc.
DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
posted
I'm not sure what Celgene is but thanks I will check it out. Don't think I'm negative on this company. I think it has great potential, I think it needs help from big money to make it go.
Posts: 271 | Registered: Jul 2006
| IP: Logged |
posted
DNAPrint Announces Discovery of Genetic Marker for Statin-Induced Myalgia Market Wire
SARASOTA, FL -- (MARKET WIRE) -- 12/19/06 -- DNAPrint Genomics, Inc. (OTCBB: DNAG), today announced that the Company's research staff has discovered a genetic marker for statin-induced myalgia (chronic muscle pain), that a patent has been filed to protect the discovery and that the research on which the discovery is based will be published in an upcoming issue of The Journal of Pharmacogenetics and Genomics (JPG).
The marker was the primary discovery from the Company's Statnome project initiated in 2000 and the manuscript to be published in JPG describes the validation of this finding in different patient samples.
"Myalgia or chronic muscle pain is a common side effect reported by patients who take statins for cholesterol control, and it is likely to be part of a disease continuum that includes myositis and rhabdomyolysis, which is a breakdown of muscle fibers that frequently results in kidney damage and is a potentially fatal side-effect," according to DNAPrint Chief Science Officer Tony Frudakis, Ph.D. "Deaths associated with statin-induced rhabdoymyolysis lead Bayer to withdraw Cerivistatin in 2001. We are satisfied to have brought one of our first pharmacogenetics programs full circle from discovery through validation and we consider the R&D phase for this project complete. With the filing of a patent to protect this discovery, the Company will be able to develop a proprietary test for this gene variant and thereby reduce the likelihood of illness or death in those patients who are taking statins. This study also criticizes the original clinical trials for statins, which did not fully or adequately explore the relationship between statins and myalgia or even rhabdomyolysis."
"This is the culmination of a project that was begun when the company was founded," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "It has taken until now to validate the original findings, but validated they are. The Company has filed a patent to protect this process. We plan to bring to market a definitive test product to identify this genetic variant and to potentially prevent painful -- and in some cases, fatal -- side effects in thousands of patients who are taking a very common prescription drug."
DNAPrint's study of 750 patients who had taken either atorvastatin (Lipitor®) or simvastatin (Zocor®) showed that patients carrying one specific genetic marker were approximately 2.5 times more likely to experience mild to severe muscle pain (myalgia). The effect was most pronounced for atorvastatin and the study showed that approximately one half of the patients who were removed from atorvastatin therapy due to muscle symptoms possess this genetic marker, whereas in the general population (with and without cardiovascular disease) only approximately 15%-25% of people carry the marker. DNAPrint applied its technology for measuring population structure (e.g., ancestry) in order to prove that the finding in both the discovery and validation samples was genuine, and in so doing received praise from JPG reviewers. This observation indicates that the genetic marker may be related not only to response to statins but also to a possible relationship with higher cholesterol levels, according to the study.
"DNA Print Genomics was founded on the underlying genomic screening methods developed to more efficiently scan the genome for medically important genetic markers of drug responses," stated Dr. Frudakis. "The current findings are another example of the efficiency of the Company's methods."
About DNAPrint Genomics, Inc.
DNAPrint Genomics, Inc. ( www.dnaprint.com ) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.
-------------------- Veni Vidi Vici Posts: 529 | From: CA | Registered: Jan 2005
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
